Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic landscape of hyperleukocytic acute myeloid leukemia.
Largeaud L, Bertoli S, Bérard E, Tavitian S, Picard M, Dufrechou S, Prade N, Vergez F, Rieu JB, Luquet I, Sarry A, Huguet F, Ruiz J, De Mas V, Delabesse E, Récher C. Largeaud L, et al. Among authors: berard e. Blood Cancer J. 2022 Jan 5;12(1):4. doi: 10.1038/s41408-021-00601-5. Blood Cancer J. 2022. PMID: 34987148 Free PMC article. No abstract available.
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, Dobbelstein S, Dastugue N, Mansat-De Mas V, Delabesse E, Duchayne E, Demur C, Sarry A, Lauwers-Cances V, Laurent G, Attal M, Récher C. Bertoli S, et al. Among authors: berard e. Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30. Blood. 2013. PMID: 23365464 Free article.
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.
Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C. Bertoli S, et al. Among authors: berard e. Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262. Oncotarget. 2016. PMID: 27852053 Free PMC article.
Improved outcome for AML patients over the years 2000-2014.
Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, Delabesse E, Sarry A, Laurent G, Attal M, Huguet F, Bérard E, Récher C. Bertoli S, et al. Among authors: berard e. Blood Cancer J. 2017 Nov 29;7(12):635. doi: 10.1038/s41408-017-0011-1. Blood Cancer J. 2017. PMID: 29184070 Free PMC article.
Dexamethasone in hyperleukocytic acute myeloid leukemia.
Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C. Bertoli S, et al. Among authors: berard e. Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8. Haematologica. 2018. PMID: 29519869 Free PMC article.
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome.
Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande AC, Despas F, Pigneux A, Récher C. Dumas PY, et al. Among authors: berard e. Blood Adv. 2020 Aug 25;4(16):3840-3849. doi: 10.1182/bloodadvances.2020002511. Blood Adv. 2020. PMID: 32790847 Free PMC article.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Galtier J, Alric C, Bérard E, Leguay T, Tavitian S, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, de Grande AC, Sarry A, Pigneux A, Récher C, Bertoli S, Dumas PY. Galtier J, et al. Among authors: berard e. Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y. Blood Cancer J. 2021. PMID: 34775463 Free PMC article. No abstract available.
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Gadaud N, Leroy H, Bérard E, Tavitian S, Leguay T, Dimicoli-Salazar S, Rieu JB, Luquet I, Largeaud L, Bidet A, Delabesse E, Klein E, Sarry A, de Grande AC, Bories P, Pigneux A, Récher C, Dumas PY, Bertoli S. Gadaud N, et al. Among authors: berard e. Leuk Lymphoma. 2022 Jun;63(6):1398-1406. doi: 10.1080/10428194.2021.2022140. Epub 2022 Jan 4. Leuk Lymphoma. 2022. PMID: 35634787
285 results